Innovative Biospecimen Science Technologies for Basic & Clinical Cancer Research

Innovative Biospecimen Science Technologies for Basic & Clinical Cancer Research

Early-stage technology development to improve collection, handling, processing, preservation, storage, and quality assessment of cancer-relevant biospecimens. Part of NCI’s IMAT program; high-risk, high-impact concepts encouraged.

Eligibility Criteria:

  • Universities, nonprofits, for-profits, governments; foreign organizations eligible (foreign components allowed).

  • PD/PI with appropriate expertise; eRA Commons/Grants.gov registrations required.

  • Multidisciplinary teams encouraged; clinical trials not allowed.

Funding Details:

  • Mechanism: R61 (exploratory/developmental).

  • Budget: up to USD 150,000 USD direct costs/year.

  • Project period: up to 3 years.

  • Expected FY26 funding: 4 awards (1M USD total).

Deadline:

  • Due: October 3, 2025 (5:00 PM local time).

  • FOA: RFA-CA-25-003.

Where to Go for Further Information: